Kotak Invests ₹940 Crore in Neuberg Diagnostics to Drive Expansion and IPO Preparation

NICE Recommends Olaparib for BRCA-Mutated Advanced Breast Cancer

SOPHiA GENETICS and Platomics Collaborate to Streamline IVDR Compliance for Clinical Labs

India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Renovaro to Acquire Predictive Oncology in All-Stock Deal

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Home
/
update
/
details

Oxford Nanopore Technologies and Plasmidsaurus Forge Strategic Partnership to Enhance Plasmid Sequencing

NextEdge Admin

24 Jul 2024

2 min 8 sec

gene therapy,Oxford Nanopore Technologies

Oxford Nanopore Technologies and Plasmidsaurus have announced an expanded, multi-year contract and collaboration to revolutionize the plasmid sequencing market with nanopore technology. Plasmidsaurus, known for its rapid, whole-plasmid sequencing service using nanopore sequencing, delivers overnight results and comprehensive datasets. Founded in 2021, Plasmidsaurus has opened nine labs in three countries and is expanding its network of 660 dropboxes and labs in biotech hubs across the US, Europe, and Asia.

Traditional plasmid sequencing methods, such as Sanger sequencing, are hindered by short read lengths and difficulties with GC-rich or repetitive DNA. Oxford Nanopore's technology overcomes these challenges, offering real-time, long-read sequencing that is more efficient and cost-effective, saving significant time and resources lost to faulty plasmids.

Gordon Sanghera, CEO of Oxford Nanopore, highlighted the collaboration's potential to advance synthetic biology and biotechnology through the unique capabilities of nanopore technology. The partnership aims to drive market growth and provide top-tier sequencing services globally.

Looking ahead, Oxford Nanopore and Plasmidsaurus will co-develop new technologies, reagents, and applications beyond plasmid sequencing, targeting microbial and gene therapy use cases to meet evolving market needs. Mark Budde, CEO of Plasmidsaurus, expressed excitement about the partnership, emphasizing the transformative potential of Oxford Nanopore’s advanced sequencing technology and their joint efforts to address the daily needs of biotech researchers worldwide.